# A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male

> **NCT02919800** · PHASE1 · COMPLETED · sponsor: **OPKO Health, Inc.** · enrollment: 32 (actual)

## Conditions studied

- Hemophilia A or B With Inhibitors

## Interventions

- **BIOLOGICAL:** MOD-5014
- **OTHER:** MOD-5014 Placebo

## Key facts

- **NCT ID:** NCT02919800
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-01-22
- **Primary completion:** 2018-02-21
- **Final completion:** 2018-02-21
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2019-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02919800

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02919800, "A Single-dose, Dose-escalation Study of a Long-acting MOD-5014 in Healthy Adult Male". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT02919800. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*